Immunization to prevent congenital cytomegalovirus infection

British Medical Bulletin

Volumn 107, Issue 1, 2013, Pages 57-68

  Adler, Stuart P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cytomegalovirus; Pregnancy; Vaccines

Indexed keywords

ANTIBODY; ANTIGEN; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; GLYCOPROTEIN; LIVE VACCINE; MIFAMURTIDE; MONOCLONAL ANTIBODY; PEPTIDE VACCINE; VIRUS ANTIGEN;

ARTICLE; AWARENESS; CONGENITAL CYTOMEGALOVIRUS INFECTION; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; ENDOTHELIUM CELL; EPITHELIUM CELL; FETAL INFECTION; FIBROBLAST; GENE; HUMAN; HUMAN CELL; IMMUNIZATION; INFECTION; MEDICAL RESEARCH; PHYSICAL DISEASE BY BODY FUNCTION; PLACENTAL INFECTION; PRIORITY JOURNAL; VACCINATION; VIRUS ENTRY; VIRUS INACTIVATION; WILD TYPE; ACTIVE IMMUNIZATION; DISEASE TRANSMISSION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; HEARING IMPAIRMENT; IMMUNOGENICITY; INFECTION PREVENTION; INNATE IMMUNITY; INTRAUTERINE INFECTION; LOW RISK POPULATION; MATERNAL CARE; MENTAL DEFICIENCY; NEWBORN DISEASE; NONHUMAN; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREGNANCY; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; VIREMIA; VIRUS GENE; VIRUS SHEDDING; VIRUS STRAIN;

EID: 84887872696     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldt023     Document Type: Article

References (47)

1. Morton CC, Nance WE. Newborn hearing screening - a silent revolution. N Engl J Med 2006;18: 2151-64.
2. Fowler KB, Stagno S, Pass RF et al. The outcome of congenital CMV infection in relation to maternal antibody status. N Engl J Med 1992;326: 663-7.
3. Adler SP. Congential cytomegalovirus screening. Pediatr Infect Dis J 2005;24: 1105-06.
4. Stagno S, Pass RF, Cloud G et al. Primary cytomegalovirus infection in pregnancy. incidence, transmission to fetus, and clinical outcome. JAMA 1986;256: 1904-8.
5. Boppanna SB, Fowler KB, Stagno S et al. Symptomatic congenital cytomegalovirus infection in infants born of mothers with preexisting immunity to cytomegalovirus. Pediatrics 1999;104: 55-6.
6. Stratton K, Durch J, Lawrence R. Vaccines for the 21st Century: A Tool for Decisionmaking, Vol. 1.Washington, DC: National Academy Press, 2001, 476.
7. Schleiss MR, Bourne N, Stroup G et al. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 2004;189: 1374-81.
8. Schleiss MR. Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus. J Clin Virol 2002;2:S37-49.
9. Bia FJ, Miller SA, Lucia HL et al. Vaccination against transplacental cytomegalovirus transmission: vaccine reactivation and efficacy in guinea pigs. J Infect Dis 1984;149: 355-62.
10. Chatterjee A, Harrison CJ, Britt WJ et al. Modification of maternal and congenital cytomegalovirus infection anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis 2001; 183: 547-53.
11. Bratcher DF, Bourne N, Bravo FJ et al. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 1995;172: 944-50.
12. Bia FJ, Griffith BP, TarisoMet al. Vaccination for the prevention of maternal and fetal infection with guinea pig cytomegalovirus. J Infect Dis 1980;142: 732-8.
13. Schleiss MR, Lacayo JC, Belkaid Y et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 2007;195: 789-98.
14. Maidji E, Nigro G, Tabata T et al. Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection. Am J Pathol 2010;177: 1298-310.
15. La Torre R, Nigro G, MazzoccoMet al. Placental enlargement in women with a primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis 2006;43: 994-1000.
16. Nigro G, Adler SP, La Torre R et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005;353: 1350-6.
17. Boppana SB, Rivera LB, Fowler KB et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001;344: 1366-71.
18. Yamamoto AY, Mussi-Pinhata MM, Boppana SB. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol 2010;202: 297-8.
19. Ross SA, Fowler KB, Ashrith G et al. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J Pediatr 2006;148: 332-6.
20. de Vries JJ, van Zwet EW, Dekker FW et al. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Rev Med Virol. 2013. doi:10.1002/rmv.1744.
21. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003;289: 1008-11.
22. Sabbaj S, Pass RF, Goepfert PA et al. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J Infect Dis 2011;203: 1534-41.
23. Adler SP, Starr SE, Plotkin SA et al. Immunity induced by a primary cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995;171: 26-32.
24. Plotkin SA, Starr SE, Friedman HM et al. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989;159: 860-5.
25. Nigro G, Adler SP, Parruti G et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy - a case-control study of the outcome in children. J Infect Dis 2012;205: 215-2.
26. Visentin S, Manara R, Milanese L et al. Early primary CMV infection in pregnancy: maternal hyperimmune globulin therapy improves children's outcome at one year. Clin Infect Dis 2012;55: 497-503.
27. Adler SP. Cytomegalovirus and child day care: risk factors for maternal infection. Pediatr Infect Dis J. 1991;10: 590-4.
28. Marshall BC, Adler SP. The frequency of pregnancy and exposure to cytomegalovirus (CMV) infections among women with a young child in day care. Am J Obs Gyn. 2009;200: 161-5.
29. Adler SP, Finney JW, Manganello AM et al. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr 2004;145: 485-91.
30. Mitchell DK, Holmes SJ, Burke RL et al. Immunogenicity of a recombinant human cytomegalovirus (CMV) gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002;21: 133-8.
31. Chen SF, Tu WW, Sharp MA et al. Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood. J Infect Dis 2004;189: 1619-27.
32. Tu W, Chen S, Sharp M et al. Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 2004;172: 3260-7.
33. Frey SE, Harrison C, Pass RF et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein b subunit vaccine. J Infect Dis 1999;180: 1700-3.
34. Adler SP, Hempfling SH, Starr SE et al. Evaluation of the safety and immunogenicity of the Towne strain of cytomegalovirus among women of childbearing age and children. Pediatr Infect Dis J 1998;17: 200-6.
35. Jacobson MA, Sinclair E, Bredt B et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin 12. Vaccine 2006;24: 5311-19.
36. Jacobson MA, Sinclair E, Bredt B et al. Cytomegalovirus (CMV) antigen-specific CD4+ and CD8+ T cell proliferation and IFN gamma responses in CMV-seronegative recipients of Towne CMV vaccine. J Clin Virol 2006;35: 332-7.
37. Heineman TC, Schleiss M, Bernstein DI et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006;193: 1350-60.
38. Urban M, Klein M, Britt WJ et al. Glycprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 1996;77: 1537-47.
39. Shimamura M, Mach M, Britt WJ. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 2006;80: 4591-600.
40. Fouts AE, Chan P, Stephan JP et al. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 2012;86: 7444-7.
41. Hahn G, Revello MG, Patrone M et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004;78: 10023-33.
42. Gerna G, Percivalle E, Lilleri D et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 2005;86: 275-84.
43. Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005;79: 10330-8.
44. Cui X, Meza BP, Adler SP et al. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008;26: 5760-6.
45. Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009;360: 1191-9.
46. Sauer A, Saccoccioa F, Cui X et al. Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine 2011;29: 2705-1.
47. Fleiss JL, Statistical Methods for Rates and Proportions (2nd edn). New York:Wiley, 1981.